PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity

BACKGROUND: Blocking programmed death-1 (PD-1) is considered to be a promising strategy to improve T cell function, and this is being explored in many ongoing clinical trials. In fact, our knowledge about PD-1 is primarily based on the results of short-term experiments or observations, but how long-...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Jianshu, Luo, Can, Wang, Yao, Guo, Yelei, Dai, Hanren, Tong, Chuan, Ti, Dongdong, Wu, Zhiqiang, Han, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686487/
https://www.ncbi.nlm.nih.gov/pubmed/31391096
http://dx.doi.org/10.1186/s40425-019-0685-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686487/
https://www.ncbi.nlm.nih.gov/pubmed/31391096
http://dx.doi.org/10.1186/s40425-019-0685-y

Ejemplares similares